Now with 111 pharmacies participating in NAC's Medical Cannabis Management System, National Access Cannabis Medical continues to expand its base of partner pharmacies across Canada
OTTAWA, Oct. 22, 2018 /CNW/ - National Access Cannabis Corp. ("NAC" or the "Company") (TSXV: META), a best practices leader in delivering secure, safe, and responsible access to legal cannabis in Canada today announced the signing of Pharmacy Cannabis Program Agreements with 70 pharmacies in Canada that will be participating in the National Access Cannabis Medical Inc. ("NACM") Medical Cannabis Management System™ ("MCMS") in addition to those announced in April 2018, bringing the total number of pharmacies working with NACM to 111.
"We see this as tremendous growth for NAC," said Mark Goliger, CEO of NAC. "This unique pharmacy partnership is a key pillar of our diversified cannabis business. The medical cannabis market in Canada is forecast to surpass $2B by 2020 (Deloitte, 2018), and as experienced medical clinic operators, we're excited to grow our medical division and broaden our ability to provide safe and responsible access to legal medical cannabis."
"The pharmacy application of the Medical Cannabis Management System provides a structured process and opportunity for independent pharmacies to enhance their involvement in medical cannabis therapy, by utilizing resources provided by NACM," explained Pram Sandhu, VP Medical Operations & Business Optimization. "It was designed with input from pharmacists, for pharmacists. We're thrilled by the opportunity to work with our new pharmacy partners toward the collective goal of improving medical cannabis related patient care."
MCMS provides pharmacies with a turnkey medical cannabis program for their patients and, when legally permissible, assistance with management of product sourcing and distribution. The MCMS program roll-out was recently initiated with the on-boarding of a pilot pharmacy, a 2-day educational event for healthcare providers, and plans for systematic training to be launched across partner pharmacies in Ontario, British Columbia, Alberta and Saskatchewan. NACM continues to negotiate with pharmacies across Canada and is on target to enter into agreements with more than 150 pharmacies by late 2018-early 2019.
NACM facilitates the safe and responsible use of medical cannabis by connecting patients with knowledgeable healthcare practitioners, coordinating clinic visits, managing medical cannabis education, providing assistance with product selection, coordinating patient registration with Health Canada approved Licensed Producers (LPs) and continued patient follow-up. After an initial on-boarding period, NACM anticipates assisting more than 200 potential medical cannabis patients per pharmacy per year, through its current roster of 111 partner pharmacies.
About National Access Cannabis Corp.
NAC is a best practices leader in delivering secure, safe, and responsible access to legal cannabis in Canada. Through its Canada-wide network of medical cannabis clinics, partner pharmacies, NAC Bio's clinical research division, NewLeaf Cannabis™ and Meta Cannabis Supply Co.™ recreational cannabis retail stores, NAC enables patients and the public to gain knowledge and access to Canada's network of authorized Licensed Producers of cannabis. NAC is listed on the TSX Venture Exchange under the symbol (TSXV: META).
For more information, visit:
This news release contains forward looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward looking statements or information. Forward-looking statements and information in this news release includes, but is not limited to, entering into additional agreements with pharmacies, and changing regulations to permit NAC to assist pharmacies with product sourcing and distribution. Although the Company believes that the expectations and assumptions on which the forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company cannot give any assurance that they will prove to be correct. Since forward looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results and developments may differ materially from those that are currently contemplated by these statements depending on, among other things, risks relating to the ability to obtain or maintain licenses to retail cannabis products; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; and the medical and potential cannabis industry in Canada generally. The Company cautions that the foregoing list of risks and uncertainties is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE National Access Cannabis Corp.
For further information: National Access Cannabis: Mark Goliger, Chief Executive Officer, National Access Cannabis, 1-800-411-1126, Info@nationalaccesscannabis.com; Investor Relations: Emily Gibbs, LodeRock Advisors Inc., 416-546-8775, firstname.lastname@example.org; Media Inquiries: Jessica Patriquin, 416.640.5525 x 230, M 416.995.8496, E email@example.com